Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.
OBJECTIVE
To evaluate the safety and efficacy, by measuring antifactor Xa levels, of enoxaparin 1 mg/kg subcutaneously once every 24 hours in patients with severe renal failure.


METHODS
Prospective study.


METHODS
Emergency, internal medicine, geriatrics, and cardiology departments of a medical center in Israel.


METHODS
Nineteen patients with stage 4 or 5 chronic kidney disease who required full anticoagulation.


METHODS
Patients received enoxaparin 1 mg/kg subcutaneously every 24 hours for 2 or more days, as determined by a treating physician.


RESULTS
Data on patients' demographic and clinical characteristics were collected. Blood samples for peak and trough antifactor Xa levels were obtained during the enoxaparin treatment period. Of the 19 study patients, 14 (74%) had peak antifactor Xa levels within the recommended range for full anticoagulation of 0.5-1.0 U/ml after their first enoxaparin dose; no concentration exceeded 1.0 U/ml. The mean peak antifactor Xa level was not significantly different after the first enoxaparin dose compared with the second and third doses. The mean +/- SD trough antifactor Xa level, thought to be an indicator of drug accumulation, was 0.12 +/- 0.12 U/ml; its clinical significance and target range are still unknown. No major bleeding events were noted.


CONCLUSIONS
Enoxaparin 1 mg/kg once every 24 hours in patients with stage 4 or 5 chronic kidney disease who required full anticoagulation was safe, and this dose did not exceed recommended concentrations. The significance of enoxaparin trough levels remains unclear and should be investigated in future studies. Other dosing regimens of enoxaparin for specific patient populations should also be assessed for safety and efficacy.
Lachish
Tamar
T
Department of Internal Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.
Rudensky
Bernard
B
Slotki
Itzchak
I
Zevin
Shoshana
S
D000368:Aged; D000369:Aged, 80 and over; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017984:Enoxaparin / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D015951:Factor Xa / Q000032:analysis*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D007557:Israel; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D051437:Renal Insufficiency / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome
D017984:Enoxaparin; D005343:Fibrinolytic Agents; D015951:Factor Xa